ID   AL3A2_HUMAN             Reviewed;         485 AA.
AC   P51648; Q6I9T3; Q93011; Q96J37;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 172.
DE   RecName: Full=Fatty aldehyde dehydrogenase;
DE            EC=1.2.1.3;
DE   AltName: Full=Aldehyde dehydrogenase 10;
DE   AltName: Full=Aldehyde dehydrogenase family 3 member A2;
DE   AltName: Full=Microsomal aldehyde dehydrogenase;
GN   Name=ALDH3A2; Synonyms=ALDH10, FALDH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   VARIANTS SLS, AND INVOLVEMENT IN SLS.
RX   PubMed=8528251; DOI=10.1038/ng0196-52;
RA   de Laurenzi V., Rogers G.R., Hamrock D.J., Marekov L.N.,
RA   Steinert P.M., Compton J.G., Markova N., Rizzo W.B.;
RT   "Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde
RT   dehydrogenase gene.";
RL   Nat. Genet. 12:52-57(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=9027499; DOI=10.1006/geno.1996.4501;
RA   Rogers G.R., Markova N.G., De Laurenzi V., Rizzo W.B., Compton J.G.;
RT   "Genomic organization and expression of the human fatty aldehyde
RT   dehydrogenase gene (FALDH).";
RL   Genomics 39:127-135(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=9070922; DOI=10.1006/geno.1996.4547;
RA   Chang C., Yoshida A.;
RT   "Human fatty aldehyde dehydrogenase gene (ALDH10): organization and
RT   tissue-dependent expression.";
RL   Genomics 40:80-85(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   FUNCTION.
RX   PubMed=22633490; DOI=10.1016/j.molcel.2012.04.033;
RA   Nakahara K., Ohkuni A., Kitamura T., Abe K., Naganuma T., Ohno Y.,
RA   Zoeller R.A., Kihara A.;
RT   "The Sjogren-Larsson syndrome gene encodes a hexadecenal dehydrogenase
RT   of the sphingosine 1-phosphate degradation pathway.";
RL   Mol. Cell 46:461-471(2012).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   VARIANT SLS SER-315.
RX   PubMed=9254849; DOI=10.1007/s004390050490;
RA   Sillen A., Jagell S., Wadelius C.;
RT   "A missense mutation in the FALDH gene identified in Sjogren-Larsson
RT   syndrome patients originating from the northern part of Sweden.";
RL   Hum. Genet. 100:201-203(1997).
RN   [13]
RP   VARIANTS SLS ARG-106; TRP-226; ASN-245; SER-315; LEU-365 AND ARG-412.
RX   PubMed=9829906;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<377::AID-HUMU3>3.0.CO;2-I;
RA   Sillen A., Anton-Lamprecht I., Braun-Quentin C., Kraus C.S.,
RA   Sayli B.S., Ayuso C., Jagell S., Kuester W., Wadelius C.;
RT   "Spectrum of mutations and sequence variants in the FALDH gene in
RT   patients with Sjoegren-Larsson syndrome.";
RL   Hum. Mutat. 12:377-384(1998).
RN   [14]
RP   VARIANTS SLS PHE-45; ASP-64; ARG-106; LEU-114; LEU-121; ARG-184;
RP   MET-184; ALA-185; CYS-228; TYR-237; ASN-245; ASN-266; ASN-279;
RP   SER-315; ILE-328; LEU-365; ARG-406; TYR-411; ASN-415; SER-419; HIS-423
RP   AND GLU-447.
RX   PubMed=10577908; DOI=10.1086/302681;
RA   Rizzo W.B., Carney G., Lin Z.;
RT   "The molecular basis of Sjoegren-Larsson syndrome: mutation analysis
RT   of the fatty aldehyde dehydrogenase gene.";
RL   Am. J. Hum. Genet. 65:1547-1560(1999).
RN   [15]
RP   VARIANT SLS SER-386.
RX   PubMed=10792573; DOI=10.1046/j.1523-1747.2000.00960-5.x;
RA   Aoki N., Suzuki H., Ito K., Ito M.;
RT   "A novel point mutation of the FALDH gene in a Japanese family with
RT   Sjoegren-Larsson syndrome.";
RL   J. Invest. Dermatol. 114:1065-1066(2000).
CC   -!- FUNCTION: Catalyzes the oxidation of long-chain aliphatic
CC       aldehydes to fatty acids. Active on a variety of saturated and
CC       unsaturated aliphatic aldehydes between 6 and 24 carbons in
CC       length. Responsible for conversion of the sphingosine 1-phosphate
CC       (S1P) degradation product hexadecenal to hexadecenoic acid.
CC       {ECO:0000269|PubMed:22633490}.
CC   -!- CATALYTIC ACTIVITY: An aldehyde + NAD(+) + H(2)O = a carboxylate +
CC       NADH.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:P30839}; Single-pass membrane protein
CC       {ECO:0000255}; Cytoplasmic side {ECO:0000250|UniProtKB:P30839}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P51648-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P51648-2; Sequence=VSP_001283;
CC   -!- DISEASE: Sjoegren-Larsson syndrome (SLS) [MIM:270200]: An
CC       autosomal recessive neurocutaneous disorder characterized by a
CC       combination of severe mental retardation, spastic di- or
CC       tetraplegia and congenital ichthyosis. Ichthyosis is usually
CC       evident at birth with varying degrees of erythema and scaling,
CC       neurologic symptoms appear in the first or second year of life.
CC       Most patients have an IQ of less than 60. Additional clinical
CC       features include glistening white spots on the retina, seizures,
CC       short stature and speech defects. {ECO:0000269|PubMed:10577908,
CC       ECO:0000269|PubMed:10792573, ECO:0000269|PubMed:8528251,
CC       ECO:0000269|PubMed:9254849, ECO:0000269|PubMed:9829906}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the aldehyde dehydrogenase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L47162; AAB01003.1; -; mRNA.
DR   EMBL; U75296; AAC50966.1; -; Genomic_DNA.
DR   EMBL; U75286; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75287; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75288; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75289; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75290; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75291; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75292; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75293; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75294; AAC50966.1; JOINED; Genomic_DNA.
DR   EMBL; U75295; AAC50965.1; -; Genomic_DNA.
DR   EMBL; U75286; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75287; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75288; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75289; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75290; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75291; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75292; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75293; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U75294; AAC50965.1; JOINED; Genomic_DNA.
DR   EMBL; U46689; AAC51121.1; -; mRNA.
DR   EMBL; AK292381; BAF85070.1; -; mRNA.
DR   EMBL; AK315096; BAG37560.1; -; mRNA.
DR   EMBL; CR457422; CAG33703.1; -; mRNA.
DR   EMBL; CH471212; EAW50898.1; -; Genomic_DNA.
DR   EMBL; BC002430; AAH02430.1; -; mRNA.
DR   CCDS; CCDS11210.1; -. [P51648-1]
DR   CCDS; CCDS32589.1; -. [P51648-2]
DR   RefSeq; NP_000373.1; NM_000382.2. [P51648-1]
DR   RefSeq; NP_001026976.1; NM_001031806.1. [P51648-2]
DR   RefSeq; XP_011522034.1; XM_011523732.1. [P51648-2]
DR   RefSeq; XP_011522035.1; XM_011523733.1. [P51648-2]
DR   RefSeq; XP_016879845.1; XM_017024356.1. [P51648-1]
DR   RefSeq; XP_016879846.1; XM_017024357.1. [P51648-1]
DR   UniGene; Hs.499886; -.
DR   PDB; 4QGK; X-ray; 2.10 A; A/B=1-460.
DR   PDBsum; 4QGK; -.
DR   ProteinModelPortal; P51648; -.
DR   SMR; P51648; -.
DR   BioGrid; 106726; 69.
DR   IntAct; P51648; 44.
DR   STRING; 9606.ENSP00000345774; -.
DR   DrugBank; DB00157; NADH.
DR   SwissLipids; SLP:000000198; -.
DR   iPTMnet; P51648; -.
DR   PhosphoSitePlus; P51648; -.
DR   SwissPalm; P51648; -.
DR   BioMuta; ALDH3A2; -.
DR   DMDM; 1706379; -.
DR   EPD; P51648; -.
DR   PaxDb; P51648; -.
DR   PeptideAtlas; P51648; -.
DR   PRIDE; P51648; -.
DR   DNASU; 224; -.
DR   Ensembl; ENST00000176643; ENSP00000176643; ENSG00000072210. [P51648-1]
DR   Ensembl; ENST00000339618; ENSP00000345774; ENSG00000072210. [P51648-2]
DR   Ensembl; ENST00000395575; ENSP00000378942; ENSG00000072210. [P51648-1]
DR   Ensembl; ENST00000579855; ENSP00000463637; ENSG00000072210. [P51648-1]
DR   Ensembl; ENST00000581518; ENSP00000461916; ENSG00000072210. [P51648-2]
DR   GeneID; 224; -.
DR   KEGG; hsa:224; -.
DR   UCSC; uc002gwa.2; human. [P51648-1]
DR   CTD; 224; -.
DR   DisGeNET; 224; -.
DR   GeneCards; ALDH3A2; -.
DR   HGNC; HGNC:403; ALDH3A2.
DR   HPA; CAB020692; -.
DR   HPA; HPA014769; -.
DR   MalaCards; ALDH3A2; -.
DR   MIM; 270200; phenotype.
DR   MIM; 609523; gene.
DR   neXtProt; NX_P51648; -.
DR   OpenTargets; ENSG00000072210; -.
DR   Orphanet; 816; Sjogren-Larsson syndrome.
DR   PharmGKB; PA24698; -.
DR   eggNOG; KOG2456; Eukaryota.
DR   eggNOG; COG1012; LUCA.
DR   GeneTree; ENSGT00390000002825; -.
DR   HOGENOM; HOG000271515; -.
DR   HOVERGEN; HBG050483; -.
DR   InParanoid; P51648; -.
DR   KO; K00128; -.
DR   OMA; IKLMLRF; -.
DR   OrthoDB; EOG091G05HC; -.
DR   PhylomeDB; P51648; -.
DR   TreeFam; TF314264; -.
DR   BioCyc; MetaCyc:HS01061-MONOMER; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   Reactome; R-HSA-389599; Alpha-oxidation of phytanate.
DR   SABIO-RK; P51648; -.
DR   ChiTaRS; ALDH3A2; human.
DR   GenomeRNAi; 224; -.
DR   PRO; PR:P51648; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000072210; -.
DR   CleanEx; HS_ALDH3A2; -.
DR   ExpressionAtlas; P51648; baseline and differential.
DR   Genevisible; P51648; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005778; C:peroxisomal membrane; TAS:Reactome.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0004029; F:aldehyde dehydrogenase (NAD) activity; IDA:UniProtKB.
DR   GO; GO:0004030; F:aldehyde dehydrogenase [NAD(P)+] activity; IEA:InterPro.
DR   GO; GO:0046577; F:long-chain-alcohol oxidase activity; IDA:UniProtKB.
DR   GO; GO:0050061; F:long-chain-aldehyde dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0052814; F:medium-chain-aldehyde dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0006081; P:cellular aldehyde metabolic process; IDA:UniProtKB.
DR   GO; GO:0007417; P:central nervous system development; IMP:UniProtKB.
DR   GO; GO:0008544; P:epidermis development; IMP:UniProtKB.
DR   GO; GO:0001561; P:fatty acid alpha-oxidation; TAS:Reactome.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0007422; P:peripheral nervous system development; IMP:UniProtKB.
DR   GO; GO:0033306; P:phytol metabolic process; IMP:UniProtKB.
DR   GO; GO:0006714; P:sesquiterpenoid metabolic process; IDA:UniProtKB.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   Gene3D; 3.40.605.10; -; 1.
DR   InterPro; IPR016161; Ald_DH/histidinol_DH.
DR   InterPro; IPR016160; Ald_DH_CS_CYS.
DR   InterPro; IPR029510; Ald_DH_CS_GLU.
DR   InterPro; IPR016162; Ald_DH_N.
DR   InterPro; IPR015590; Aldehyde_DH_dom.
DR   InterPro; IPR012394; Aldehyde_DH_NAD(P).
DR   Pfam; PF00171; Aldedh; 1.
DR   PIRSF; PIRSF036492; ALDH; 1.
DR   SUPFAM; SSF53720; SSF53720; 1.
DR   PROSITE; PS00070; ALDEHYDE_DEHYDR_CYS; 1.
DR   PROSITE; PS00687; ALDEHYDE_DEHYDR_GLU; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Endoplasmic reticulum;
KW   Ichthyosis; Membrane; Mental retardation; NAD; Oxidoreductase;
KW   Phosphoprotein; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    485       Fatty aldehyde dehydrogenase.
FT                                /FTId=PRO_0000056473.
FT   TOPO_DOM      1    463       Cytoplasmic.
FT   TRANSMEM    464    480       Helical. {ECO:0000255}.
FT   NP_BIND     185    190       NAD. {ECO:0000255}.
FT   ACT_SITE    207    207       {ECO:0000255|PROSITE-ProRule:PRU10007}.
FT   ACT_SITE    241    241       {ECO:0000255|PROSITE-ProRule:PRU10008}.
FT   MOD_RES     293    293       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     482    485       AEYY -> KYQAVLRRKALLIFLVVHRLRWSSKQR (in
FT                                isoform 2). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9027499}.
FT                                /FTId=VSP_001283.
FT   VARIANT      45     45       I -> F (in SLS; severe loss of activity).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017510.
FT   VARIANT      64     64       V -> D (in SLS; severe loss of activity;
FT                                dbSNP:rs72547556).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017511.
FT   VARIANT     106    106       L -> R (in SLS; severe loss of activity;
FT                                dbSNP:rs72547558).
FT                                {ECO:0000269|PubMed:10577908,
FT                                ECO:0000269|PubMed:9829906}.
FT                                /FTId=VAR_002249.
FT   VARIANT     114    114       P -> L (in SLS; severe loss of activity;
FT                                dbSNP:rs72547559).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017512.
FT   VARIANT     121    121       P -> L (in SLS; severe loss of activity;
FT                                dbSNP:rs72547560).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017513.
FT   VARIANT     184    184       T -> M (in SLS; severe loss of activity;
FT                                dbSNP:rs72547562).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017514.
FT   VARIANT     184    184       T -> R (in SLS; severe loss of activity).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017515.
FT   VARIANT     185    185       G -> A (in SLS; severe loss of activity;
FT                                dbSNP:rs72547563).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017516.
FT   VARIANT     214    214       C -> Y (in SLS; 4% of activity;
FT                                dbSNP:rs72547564).
FT                                {ECO:0000269|PubMed:8528251}.
FT                                /FTId=VAR_002250.
FT   VARIANT     226    226       C -> W (in SLS; dbSNP:rs72547565).
FT                                {ECO:0000269|PubMed:9829906}.
FT                                /FTId=VAR_002251.
FT   VARIANT     228    228       R -> C (in SLS; severe loss of activity;
FT                                dbSNP:rs72547566).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017517.
FT   VARIANT     237    237       C -> Y (in SLS; severe loss of activity;
FT                                dbSNP:rs72547567).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017518.
FT   VARIANT     245    245       D -> N (in SLS; severe loss of activity;
FT                                originally thought to be a neutral
FT                                polymorphism; dbSNP:rs72547568).
FT                                {ECO:0000269|PubMed:10577908,
FT                                ECO:0000269|PubMed:9829906}.
FT                                /FTId=VAR_002252.
FT   VARIANT     266    266       K -> N (in SLS; mild reduction of
FT                                activity; the underlying nucleotide
FT                                substitution affects transcript
FT                                stability; dbSNP:rs72547569).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017519.
FT   VARIANT     279    279       Y -> N (in SLS; severe loss of activity;
FT                                dbSNP:rs72547570).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017520.
FT   VARIANT     314    315       AP -> GAKSTVGA (in SLS; 8% of activity).
FT                                {ECO:0000269|PubMed:8528251}.
FT                                /FTId=VAR_002253.
FT   VARIANT     315    315       P -> S (in SLS; common mutation in
FT                                Europeans; severe loss of enzymatic
FT                                activity; dbSNP:rs72547571).
FT                                {ECO:0000269|PubMed:10577908,
FT                                ECO:0000269|PubMed:9254849,
FT                                ECO:0000269|PubMed:9829906}.
FT                                /FTId=VAR_002254.
FT   VARIANT     328    328       M -> I (in SLS; dbSNP:rs72547572).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017521.
FT   VARIANT     365    365       S -> L (in SLS; severe loss of activity;
FT                                dbSNP:rs72547573).
FT                                {ECO:0000269|PubMed:10577908,
FT                                ECO:0000269|PubMed:9829906}.
FT                                /FTId=VAR_002255.
FT   VARIANT     386    386       N -> S (in SLS; dbSNP:rs72547575).
FT                                {ECO:0000269|PubMed:10792573}.
FT                                /FTId=VAR_017522.
FT   VARIANT     406    406       G -> R (in SLS).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017523.
FT   VARIANT     411    411       H -> Y (in SLS; severe loss of activity).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017524.
FT   VARIANT     412    412       G -> R (in SLS; dbSNP:rs778115541).
FT                                {ECO:0000269|PubMed:9829906}.
FT                                /FTId=VAR_002256.
FT   VARIANT     415    415       S -> N (in SLS; severe loss of activity).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017525.
FT   VARIANT     419    419       F -> S (in SLS; severe loss of activity;
FT                                dbSNP:rs72547576).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017526.
FT   VARIANT     423    423       R -> H (in SLS; severe loss of activity;
FT                                dbSNP:rs768290318).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017527.
FT   VARIANT     447    447       K -> E (in SLS; severe loss of activity;
FT                                dbSNP:rs67939114).
FT                                {ECO:0000269|PubMed:10577908}.
FT                                /FTId=VAR_017528.
FT   HELIX         1     13       {ECO:0000244|PDB:4QGK}.
FT   TURN         14     17       {ECO:0000244|PDB:4QGK}.
FT   HELIX        20     36       {ECO:0000244|PDB:4QGK}.
FT   HELIX        38     49       {ECO:0000244|PDB:4QGK}.
FT   HELIX        53     59       {ECO:0000244|PDB:4QGK}.
FT   HELIX        61     78       {ECO:0000244|PDB:4QGK}.
FT   TURN         88     92       {ECO:0000244|PDB:4QGK}.
FT   STRAND       93    101       {ECO:0000244|PDB:4QGK}.
FT   STRAND      103    108       {ECO:0000244|PDB:4QGK}.
FT   STRAND      111    113       {ECO:0000244|PDB:4QGK}.
FT   HELIX       116    127       {ECO:0000244|PDB:4QGK}.
FT   STRAND      131    135       {ECO:0000244|PDB:4QGK}.
FT   HELIX       141    154       {ECO:0000244|PDB:4QGK}.
FT   TURN        157    159       {ECO:0000244|PDB:4QGK}.
FT   STRAND      160    162       {ECO:0000244|PDB:4QGK}.
FT   HELIX       167    173       {ECO:0000244|PDB:4QGK}.
FT   STRAND      179    185       {ECO:0000244|PDB:4QGK}.
FT   HELIX       187    199       {ECO:0000244|PDB:4QGK}.
FT   STRAND      204    207       {ECO:0000244|PDB:4QGK}.
FT   STRAND      213    216       {ECO:0000244|PDB:4QGK}.
FT   STRAND      218    220       {ECO:0000244|PDB:4QGK}.
FT   HELIX       222    234       {ECO:0000244|PDB:4QGK}.
FT   HELIX       235    238       {ECO:0000244|PDB:4QGK}.
FT   STRAND      246    249       {ECO:0000244|PDB:4QGK}.
FT   HELIX       251    253       {ECO:0000244|PDB:4QGK}.
FT   HELIX       254    269       {ECO:0000244|PDB:4QGK}.
FT   HELIX       273    275       {ECO:0000244|PDB:4QGK}.
FT   HELIX       285    293       {ECO:0000244|PDB:4QGK}.
FT   TURN        294    297       {ECO:0000244|PDB:4QGK}.
FT   STRAND      300    302       {ECO:0000244|PDB:4QGK}.
FT   TURN        308    311       {ECO:0000244|PDB:4QGK}.
FT   STRAND      316    318       {ECO:0000244|PDB:4QGK}.
FT   HELIX       326    328       {ECO:0000244|PDB:4QGK}.
FT   STRAND      334    341       {ECO:0000244|PDB:4QGK}.
FT   HELIX       345    353       {ECO:0000244|PDB:4QGK}.
FT   STRAND      359    364       {ECO:0000244|PDB:4QGK}.
FT   HELIX       368    377       {ECO:0000244|PDB:4QGK}.
FT   STRAND      381    389       {ECO:0000244|PDB:4QGK}.
FT   HELIX       390    393       {ECO:0000244|PDB:4QGK}.
FT   HELIX       403    405       {ECO:0000244|PDB:4QGK}.
FT   HELIX       413    418       {ECO:0000244|PDB:4QGK}.
FT   STRAND      420    427       {ECO:0000244|PDB:4QGK}.
FT   HELIX       433    438       {ECO:0000244|PDB:4QGK}.
FT   STRAND      440    442       {ECO:0000244|PDB:4QGK}.
FT   HELIX       445    454       {ECO:0000244|PDB:4QGK}.
SQ   SEQUENCE   485 AA;  54848 MW;  209601CB5803C7E3 CRC64;
     MELEVRRVRQ AFLSGRSRPL RFRLQQLEAL RRMVQEREKD ILTAIAADLC KSEFNVYSQE
     VITVLGEIDF MLENLPEWVT AKPVKKNVLT MLDEAYIQPQ PLGVVLIIGA WNYPFVLTIQ
     PLIGAIAAGN AVIIKPSELS ENTAKILAKL LPQYLDQDLY IVINGGVEET TELLKQRFDH
     IFYTGNTAVG KIVMEAAAKH LTPVTLELGG KSPCYIDKDC DLDIVCRRIT WGKYMNCGQT
     CIAPDYILCE ASLQNQIVWK IKETVKEFYG ENIKESPDYE RIINLRHFKR ILSLLEGQKI
     AFGGETDEAT RYIAPTVLTD VDPKTKVMQE EIFGPILPIV PVKNVDEAIN FINEREKPLA
     LYVFSHNHKL IKRMIDETSS GGVTGNDVIM HFTLNSFPFG GVGSSGMGAY HGKHSFDTFS
     HQRPCLLKSL KREGANKLRY PPNSQSKVDW GKFFLLKRFN KEKLGLLLLT FLGIVAAVLV
     KAEYY
//
